No significant difference was seen in the expression of the myeloid markers (CD13, CD33, MPO), the progenitor cell markers (CD34, CD117) or the lymphatic markers (CD3, CD10, CD19, HLA-DR) between patients with and without vacuolized AML blasts (Table 2). This evidence concerns the gene CD19 and acute myeloid leukemia.